Collaborative Areas Granted

No definition available.

Name:	rgls_CollaborativeAreasGranted
Namespace Prefix:	rgls_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Common Stock Transaction Restriction Period

+ References

No definition available.

+ Details

Name:	rgls_CommonStockTransactionRestrictionPeriod
Namespace Prefix:	rgls_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Deferred Revenue Creditable Against Future Milestones

+ References

No definition available.

+ Details

Name:	rgls_DeferredRevenueCreditableAgainstFutureMilestones
Namespace Prefix:	rgls_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Deferred Revenue, Remaining Recognition Period

+ References

No definition available.

+ Details

Name:	rgls_DeferredRevenueRemainingRecognitionPeriod
Namespace Prefix:	rgls_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Fair Value Inputs Period

+ References

No definition available.

+ Details

Name:	rgls_FairValueInputsPeriod
Namespace Prefix:	rgls_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Issuance of common stock price per share.

+ References

No definition available.

+ Details

Name:	rgls_IssuanceOfCommonStockPricePerShare
Namespace Prefix:	rgls_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Percentage Of Costs Funded In License Agreement

+ References

No definition available.

+ Details

Name:	rgls_PercentageOfCostsFundedInLicenseAgreement
Namespace Prefix:	rgls_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Research and Development Plan, Expected Term

+ References

No definition available.

+ Details

Name:	rgls_ResearchAndDevelopmentPlanExpectedTerm
Namespace Prefix:	rgls_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Revenue Recognition, Milestone Method, Potential Milestone Receivable

+ References

No definition available.

+ Details

Name:	rgls_RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable
Namespace Prefix:	rgls_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Royalty Percentage Based On Net Sales

+ References

No definition available.

+ Details

Name:	rgls_RoyaltyPercentageBasedOnNetSales
Namespace Prefix:	rgls_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 30
-Article 5

+ Details

Name:	us-gaap_CommonStockSharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

+ Details

Name:	us-gaap_CommonStockValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

+ Details

Name:	us-gaap_DeferredRevenueRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Cash received from collaborators during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name:	us-gaap_ProceedsFromCollaborators
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. For cash flows, this element primarily pertains to amortization of deferred credits on long-term arrangements. As a noncash item, it is deducted from net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 13
-Section A
-Subsection 1

+ Details

Name:	us-gaap_RecognitionOfDeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 28
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=51671726&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	rgls_StrategicAlliancesAxis=rgls_AstraZenecaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rgls_RG125Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=rgls_CommonStockPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=rgls_PreclinicalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=rgls_ClinicalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=rgls_CommercializationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=rgls_SideLetterMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rgls_PreinvestigationalNewDrugAndActivePharmaceuticalIngredientManufacturingActivitiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rgls_PhaseOneClinicalStudyProductManufacturingActivitiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rgls_StrategicAlliancesAxis=rgls_SanofiMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementGeographicalAxis=country_US
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rgls_DevelopmentCommercializationAndLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=rgls_ProofofConceptTrialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=rgls_RegulatoryAndCommercializationMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rgls_StrategicAlliancesAxis=rgls_BiogenIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Strategic Alliances and Collaborations (Detail)	1 Months Ended											3 Months Ended		6 Months Ended		8 Months Ended
Strategic Alliances and Collaborations (Detail)	Dec. 31, 2015 USD ($) shares	Sep. 30, 2015 USD ($)	Jul. 31, 2015	May 31, 2015 USD ($)	Mar. 31, 2015 USD ($)	Jan. 31, 2015 USD ($)	Aug. 31, 2014 USD ($)	Feb. 28, 2014 USD ($) $ / shares shares	Jul. 31, 2013 USD ($)	Oct. 31, 2012 USD ($) $ / shares shares	Aug. 31, 2012 USD ($) target	Jun. 30, 2016 USD ($) shares	Jun. 30, 2015 USD ($)	Jun. 30, 2016 USD ($) shares	Jun. 30, 2015 USD ($)	Jan. 31, 2014 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Common stock value	$ 53,000											$ 53,000		$ 53,000
Common stock, shares issued \| shares	52,669,266											52,787,756		52,787,756
Total revenues												$ 483,000	$ 3,834,000	$ 972,000	$ 8,034,000
AstraZeneca
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of collaborative areas granted \| target											3
Initial upfront option payment										$ 3,000,000
Expected term of research and development plan (years)										4 years
Common stock value											$ 25,000,000
Common stock, shares issued \| shares										6,250,000
Price per share (in dollars per share) \| $ / shares										$ 4.00
Restriction period in which Alliances could not sell, transfer, make any short sale of, or grant any option for the sale of any common stock										365 days
Restricting common stock valuation measurement period										1 year
Deferred revenue										$ 4,300,000
Deferred revenue remaining recognition period														2 months
Potential revenue through milestone payments												485,500,000		$ 485,500,000
AstraZeneca \| Minimum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalties based on percentage of net sales														10.00%
AstraZeneca \| Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalties based on percentage of net sales														20.00%
AstraZeneca \| RG-125
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential revenue through milestone payments												160,000,000		$ 160,000,000
AstraZeneca \| Common Stock Purchase Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred revenue												200,000		200,000
AstraZeneca \| Preclinical
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments, earned					$ 2,500,000
Potential revenue through milestone payments												2,500,000		2,500,000
AstraZeneca \| Clinical
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments, earned	$ 10,000,000
Potential revenue through milestone payments												113,000,000		113,000,000
AstraZeneca \| Clinical \| RG-125
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential revenue through milestone payments												32,500,000		32,500,000
AstraZeneca \| Commercialization
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential revenue through milestone payments												370,000,000		370,000,000
AstraZeneca \| Commercialization \| RG-125
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential revenue through milestone payments												127,500,000		$ 127,500,000
AstraZeneca \| Side Letter
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total revenues													$ 600,000		$ 3,200,000
AstraZeneca \| Side Letter \| Pre-IND and API manufacturing activities
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Percentage of cost funded						50.00%
AstraZeneca \| Side Letter \| Phase I clinical study product manufacturing activities
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Percentage of cost funded						100.00%
Sanofi
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred revenue								$ 400,000
Sanofi \| Private Placement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Common stock value								$ 10,000,000
Common stock, shares issued \| shares								1,303,780
Price per share (in dollars per share) \| $ / shares								$ 7.67
Restriction period in which Alliances could not sell, transfer, make any short sale of, or grant any option for the sale of any common stock								12 months
Sanofi \| Minimum \| United States
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalties based on percentage of net sales														10.00%
Sanofi \| Minimum \| Outside of the United States
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalties based on percentage of net sales														10.00%
Sanofi \| Maximum \| United States
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalties based on percentage of net sales														20.00%
Sanofi \| Maximum \| Outside of the United States
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalties based on percentage of net sales														20.00%
Sanofi \| Development Commercialization And License Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Initial upfront option payment									$ 2,500,000
Deferred revenue creditable against future milestones								$ 1,250,000	$ 1,250,000					$ 1,250,000
Upfront payment non-creditable portion recognized																$ 1,250,000
Sanofi \| Common Stock Purchase Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred revenue												300,000		$ 300,000
Deferred revenue remaining recognition period														4 years
Sanofi \| Clinical
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential revenue through milestone payments												15,000,000		$ 15,000,000
Sanofi \| Proof-of-Concept Trial
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential revenue through milestone payments												101,800,000		101,800,000
Sanofi \| Regulatory and Commercialization Milestones
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential revenue through milestone payments												$ 300,000,000		$ 300,000,000
Biogen
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Initial upfront option payment							$ 2,000,000
Deferred revenue	$ 0
Deferred revenue remaining recognition period			14 months				1 year				12 months
Biogen \| Research and development
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments, earned		$ 300,000		$ 300,000		$ 100,000
Revenue recognized							$ 2,000,000